VRPX Virpax Pharmaceuticals
- 0.7200
- -0.0200-2.70%
Virpax Pharmaceuticals News
Maxim Group Downgrades Virpax Pharmaceuticals to Hold
Maxim Group analyst Naz Rahman downgrades Virpax Pharmaceuticals from Buy to Hold.
Virpax Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/22/2024 — Maxim Group Downgrades Buy → Hold 06/09/2022 471.43% Maxim Group → $4 Initiates Coverage On
SINTX Technologies SINT Earnings; Virpax Pharmaceuticals VRPX Earnings
Virpax Prices Public Offering of Shares, Warrants; Shares Tumble
Virpax Pharmaceuticals (VRPX) shares tumbled more than 65% in recent Wednesday trading after the company priced its public offering of slightly more than 1.6 million common shares and related warrants
NTRB, AERT and SPWR Among Mid-day Movers
Express News | Virpax Pharmaceuticals Shares Are Trading Lower After the Company Announced the Pricing of a $2.25 Million Public Offering
Virpax Pharmaceuticals Shares Hit All-Time Low After Equity Sale
By Colin Kellaher Virpax Pharmaceuticals shares slid more than 60% and hit a new all-time low on Wednesday after the biopharmaceutical company said it was raising $2.25 million in a dilutive equity o
Biocryst Pharmaceuticals, T2 Biosystems, Annovis Bio Among Healthcare Movers
Dow Jumps 200 Points; US Inflation Rate Slows In April
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 200 points on Wednesday.Following the market opening, the Dow traded up 0.54% to 39,772.77 while the NASDAQ rose 0.57
Wall Street Set to Open Modestly Higher Wednesday as Inflation Dips in April
US stocks look set to open modestly higher Wednesday as key monthly inflation data came in slightly lower than expected, while annual inflation matched analyst forecasts. The Dow Jones Industrial Aver
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results.Arcutis Biotherapeutics
Top Premarket Decliners
Virpax Pharmaceuticals (VRPX) shares dropped nearly 61% in recent Wednesday premarket activity, continuing Tuesday's 25% loss. Bolt Biotherapeutics (BOLT) shares tumbled more than 31% after Guggenheim
Investors Await Key Inflation Data for April as US Futures Remain Flat in Wednesday's Premarket
US stock futures were flat in Wednesday's premarket session as investors anxiously await key inflation data later in the morning. The Dow Jones Industrial Average futures were up 0.01%, S&P 500 future
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersSINTX Techs (NASDAQ:SINT) stock moved upwards by 143.1% to $0.13 during Wednesday's pre-market session. The company's market cap stands at $16.4 million. The company's, Q1 earnings came out 2 d
Express News | Virpax Pharmaceuticals Inc - Pricing of a Public Offering of 1.7 Mln Shares of Common Stock at $1.35 Price per Share
Express News | Virpax Announces Pricing of $2.25 Million Public Offering
JAN, MTC and PROK Among Mid-day Movers
Express News | Virpax Pharmaceuticals Shares Are Trading Lower After the Company Reported a Year-over-year Decrease in Q1 EPS Results
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersDelcath Systems (NASDAQ:DCTH) stock rose 33.2% to $7.19 during Tuesday's regular session. The company's market cap stands at $199.8 million. As per the news, the Q1 earnings report came out tod
Express News | Virpax Pharmaceuticals Q1 2024 EPS $(2.75) Down From $(1.30) YoY
Analysis
Price Target
No Data
